AmerisourceBergen Elects Lorence H. Kim, M.D., to Its Board of Directors
September 27 2022 - 7:15AM
Business Wire
AmerisourceBergen Corporation (NYSE: ABC) today announced that
its Board of Directors has elected Lorence H. Kim, M.D., 48, as a
new independent director, effective October 1, 2022. With the
election of Dr. Kim, the Board of Directors will increase from ten
to eleven members, nine of whom are independent.
“We look forward to Dr. Kim joining AmerisourceBergen’s Board of
Directors. His business acumen, deep financial expertise, and
healthcare knowledge will bring great perspective to the Board,
AmerisourceBergen, and our stakeholders,” said Jane E. Henney,
M.D., Lead Independent Director.
“Lorence’s background makes him an excellent fit for
AmerisourceBergen as we advance our strategic growth priorities and
vision,” said Steven H. Collis, Chairman, President & Chief
Executive Officer. “Lorence’s sophistication and experience in
pharmaceutical innovation will be incredibly valuable as we
continue to focus on delivering long-term sustainable growth,
guided by our purpose of being united in our responsibility to
create healthier futures.”
Dr. Kim is currently a Venture Partner at Third Rock Ventures,
LLC. From 2014 to 2020, he was the Chief Financial Officer of
Moderna, Inc. Prior to that, he spent 14 years at Goldman, Sachs
& Co., where his last role was Managing Director and Co-Head,
Biotechnology Investment Banking. Dr. Kim is a director of Cowen
Inc. and Revolution Medicines, Inc. He also serves as a director of
Abata Therapeutics, Inc., and Flare Therapeutics Inc., and was a
director at Seres Therapeutics, Inc., from 2014 to 2020. In
addition, he is a member of the Board of Governors of the American
Red Cross and a member of the Board of Trustees for Prep for
Prep.
Dr. Kim earned his bachelor’s degree in Biochemical Sciences
from Harvard University. He earned an M.B.A. in Health Care
Management from the Wharton School of the University of
Pennsylvania and an M.D. from the University of Pennsylvania School
of Medicine.
About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of
people and communities around the world by advancing the
development and delivery of pharmaceuticals and healthcare
products. As a leading global healthcare company, with a foundation
in pharmaceutical distribution and solutions for manufacturers,
pharmacies and providers, we create unparalleled access, efficiency
and reliability for human and animal health. Our 42,000 global team
members power our purpose: We are united in our responsibility to
create healthier futures. AmerisourceBergen is ranked #10 on the
Fortune 500 with more than $200 billion in annual revenue. Learn
more at investor.amerisourcebergen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220926005806/en/
Bennett S. Murphy Senior Vice President, Investor Relations
610-727-3693 bmurphy@amerisourcebergen.com
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Sep 2023 to Sep 2024